Administration of CXCL5 neutralizing antibody at 10 μg/mL doses increased the protein expression of VEGF and SDF-1 in HG-stimulated EPCs from non-DM subjects (Fig. 2C). Here, CXCL5 is linked to diabetes mellitus.